Drugs for Niemann-Pick Disease, Type a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 44)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Miglustat |
Approved |
Phase 4 |
|
72599-27-0 |
51634 |
Synonyms:
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
1,5-Dideoxy-1,5-N-butylimino-D-glucitol
134282-77-2
72599-27-0
AC1L1BHJ
Brazaves
BuDNJ
Butyldeoxynojirimycin
CHEBI:49779
CHEBI:50381
CHEMBL1029
CID51634
D05032
DB00419
HMS2090N20
LS-116261
Miglustat
Miglustat (USAN/INN)
Miglustat [USAN]
Miglustat, Hydrochloride
miglustatum
Miglustatum
N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol
N-(n-Butyl)deoxynojirimycin
N-(N-Butyl)deoxynojirimycin
|
N-(N-Butyl)deoxy-nojirimycin
NB-DNJ
N-Bu-DNJ
n-Butyl deoxynojirimycin
N-Butyl deoxynojirimycin
n-Butyl dnj
N-butyl-1-deoxynojirimycin
N-Butyl-1-deoxynojirimycin
N-Butyldeoxynojirimycin
N-Butyl-deoxynojirimycin
N-Butyl-DNJ
N-Butylmoranoline
NBV
nchembio.81-comp12
nchembio850-comp5
OGT 918
OGT-918
SC 48334
SC48334
SC-48334
UNII-ADN3S497AZ
Vevesca
Zavesca
Zavesca (TN)
|
|
2 |
|
Anti-HIV Agents |
|
Phase 4 |
|
|
|
3 |
|
Cardiac Glycosides |
|
Phase 4 |
|
|
|
4 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
5 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
6 |
|
Anti-Retroviral Agents |
|
Phase 4 |
|
|
|
7 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
8 |
|
Glycoside Hydrolase Inhibitors |
|
Phase 4 |
|
|
|
9 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
52-21-1 |
|
10 |
|
Prednisolone |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
50-24-8 |
5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
(11Î’)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-pregnadiene-3,20-dione-11β,17α,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Bio-0666
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
Codelcortone
Co-Hydeltra
CO-Hydeltra
component of Ataraxoid
component of K-Predne-Dome
Cordrol
Cortalone
Cotogesic
Cotolone
CPD000718761
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
delta(1)-Cortisol
delta(1)-Dehydrocortisol
Delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
Delta(1)-dehydrohydrocortisone
Delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Deltacortenol
Deltacortril
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
Delta-Ef-Cortelan
delta-hydrocortisone
Deltahydrocortisone
Deltasolone
Delta-stab
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
Derpo PD
Dexa-Cortidelt hostacortin H
Dexa-Cortidelt Hostacortin H
Di adreson F
Di Adreson F
Di-adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Di-Adreson-F
Dicortol
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
EINECS 200-021-7
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
Hostacortin H
HSDB 3385
Hydeltra
Hydeltrasol
Hydeltra-Tba
|
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
Inflamase Forte
Inflamase Mild
I-Pred
K 1557
Key-Pred
Klismacort
Lentosone
Lite Pred
LMST02030179
LS-7669
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
Methylprednisolone Acetate
Meticortelone
Meti-Derm
Metreton
MLS001304083
MLS002154250
MLS002207037
MolPort-002-507-147
M-Predrol
NCGC00179649-01
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
NSC 9120
NSC9120
NSC9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
PRDL
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
prednisolone
Prednisolone
Prednisolone (anhydrous)
Prednisolone (JP15/USP/INN)
Prednisolone [INN:BAN:JAN]
Prednisolone acetate
Prednisolone Acetate
Prednisolone sodium phosphate
Prednisolone Sodium Phosphate
Prednisolone tebutate
Prednisolone Tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick_404
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Rolisone
S1737_Selleck
SAM002264639
Scherisolon
SMR000718761
Solone
SPBio_002367
Steran
Sterane
Sterolone
Supercortisol
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-hydrogen
Ultracortene-Hydrogen
UNII-9PHQ9Y1OLM
ZINC03833821
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
11 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 2, Phase 3 |
|
2921-57-5 |
|
Synonyms:
Methylprednisolone hydrogen succinate
|
Methylprednisolone succinate
|
|
12 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
83-43-2 |
6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
|
Medrate
Medric acid
Medrol
Medrol (TN)
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
13 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
14 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 2, Phase 3 |
|
2920-86-7 |
|
Synonyms:
(+)-prednisolone hemisuccinate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
Prednisolone hydrogen succinate
Prednisolone succinate
|
|
15 |
|
Antilymphocyte Serum |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Methylprednisolone Acetate |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Pharmaceutical Solutions |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
Acetylcysteine |
Approved, Investigational |
Phase 1, Phase 2 |
|
616-91-1 |
12035 |
Synonyms:
(2R)-2-Acetylamino-3-sulfanylpropanoate
(2R)-2-acetylamino-3-sulfanylpropanoic acid
(2R)-2-Acetylamino-3-sulfanylpropanoic acid
(2R)-2-Acetylamino-3-sulphanylpropanoate
(2R)-2-Acetylamino-3-sulphanylpropanoic acid
(R)-2-Acetylamino-3-mercaptopropanoate
(R)-2-acetylamino-3-mercaptopropanoic acid
(R)-2-Acetylamino-3-mercaptopropanoic acid
(R)-Mercaptate
(R)-Mercaptic acid
(R)-mercapturic acid
(R)-Mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
Ac pharma brand OF acetylcysteine
ACC
Acebraus
Acemuc
Acetabs
Acetadote
Acetilcisteina
Acetylcystein al
Acetylcystein atid
Acetylcystein heumann
Acetylcystein trom
Acetylcystein, mentopin
Acetylcysteine
Acetylcysteine ac-pharma brand
Acetylcysteine alcon brand
Acetylcysteine aluid brand
Acetylcysteine atid brand
Acetylcysteine azupharma brand
Acetylcysteine betapharm brand
Acetylcysteine bioiberica brand
Acetylcysteine bouchara brand
Acetylcysteine centrafarm brand
Acetylcysteine disphar brand
Acetylcysteine farmasan brand
Acetylcysteine fresenius brand
Acetylcysteine génévrier brand
Acétylcystéine GNR
Acetylcysteine GNR-pharma brand
Acetylcysteine guerbet brand
Acetylcysteine hermes brand
Acetylcysteine heumann brand
Acetylcysteine hydrochloride
Acetylcysteine inpharzam brand
Acetylcysteine intra brand
Acetylcysteine klinge brand
Acetylcysteine krewel brand
Acetylcysteine lichtenstein brand
Acetylcysteine lindopharm brand
Acetylcysteine merck brand
Acetylcysteine oberlin brand
Acetylcysteine pfleger brand
Acetylcysteine pharbita brand
Acetylcysteine roberts brand
Acetylcysteine sodium
Acetylcysteine temmler brand
Acetylcysteine teva brand
Acetylcysteine thiemann brand
Acetylcysteine trommsdorff brand
Acetylcysteine upsa brand
Acetylcysteine whitehall brand
Acetylcysteine zambon brand
Acetylcysteine zinc
Acetylcysteine zyma brand
Acetylcysteine, (D)-isomer
Acetylcysteine, (DL)-isomer
Acetylcysteine, monoammonium salt
Acetylcysteine, monosodium salt
Acetylcysteinum
Acetylin
Acetyst
Acid, mercapturic
Ac-pharma brand OF acetylcysteine
Airbron
Alcon brand OF acetylcysteine
Allen and hanburys brand OF acetylcysteine
Aluid brand OF acetylcysteine
Alveolex
Atid brand OF acetylcysteine
Azubronchin
Azupharma brand OF acetylcysteine
Betapharm brand OF acetylcysteine
Bioiberica brand OF acetylcysteine
Bisolvon nac
Boehringer ingelheim brand OF acetylcysteine
Bouchara brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine sodium salt
Bristol-myers squibb brand OF acetylcysteine
Bristol-myers squibb brand OF acetylcysteine sodium salt
Bromuc
Broncho fips
Broncho-fips
BronchoFips
Broncholysin
Broncoclar
Centrafarm brand OF acetylcysteine
Codotussyl
Cystamucil
|
Dampo mucopect
Dey brand OF acetylcysteine sodium salt
Disphar brand OF acetylcysteine
Durabronchal
Eurespiran
Exomuc
Fabrol
Farmasan brand OF acetylcysteine
Fluimicil infantil
Fluimucetin
Fluimucil
Flumucetin
Fluprowit
Frekatuss
Fresenius brand OF acetylcysteine
Genac
Génévrier brand OF acetylcysteine
GNR Pharma brand OF acetylcysteine
GNR-Pharma brand OF acetylcysteine
Guerbet brand OF acetylcysteine
Hermes brand OF acetylcysteine
Heumann brand OF acetylcysteine
Hoestil
Hustengetränk, optipect
Hydrochloride, acetylcysteine
Ilube
Inpharzam brand OF acetylcysteine
Intra brand OF acetylcysteine
Jenacystein
Jenapharm
Klinge brand OF acetylcysteine
Krewel brand OF acetylcysteine
L-a-Acetamido-b-mercaptopropionate
L-a-Acetamido-b-mercaptopropionic acid
L-acetylcysteine
L-Acetylcysteine
L-alpha-Acetamido-beta-mercaptopropionate
L-alpha-Acetamido-beta-mercaptopropionic acid
Lantamed
Larylin nac
Lichtenstein brand OF acetylcysteine
Lindocetyl
Lindopharm brand OF acetylcysteine
Lysox
L-Α-acetamido-β-mercaptopropionate
L-α-acetamido-β-mercaptopropionic acid
L-Α-acetamido-β-mercaptopropionic acid
m Pectil
Mentopin acetylcystein
Mercaptate
Mercaptic acid
Mercapturic acid
Merck brand OF acetylcysteine
Monoammonium salt acetylcysteine
Monosodium salt acetylcysteine
m-Pectil
MPectil
Muciteran
Muco sanigen
Mucolysin
Mucomyst
Mucopect, dampo
Mucosil
Mucosol
Mucosolvin
N Acetyl L cysteine
N Acetylcysteine
NAC
NAC al
NAC zambon
NAC, bisolvon
N-Acetyl-3-mercaptoalanine
N-acetylcysteine
N-Acetylcysteine
N-Acety-L-cysteine
N-acetyl-L-(+)-cysteine
N-Acetyl-L-(+)-cysteine
N-acetyl-L-cysteine
Oberlin brand OF acetylcysteine
Optipect hustengetränk
Parvolex
Pfleger brand OF acetylcysteine
Pharbita brand OF acetylcysteine
Produpharm lappe brand OF acetylcysteine
Roberts brand OF acetylcysteine
Roche nicholas brand OF acetylcysteine
Sanigen, muco
Siccoral
Siran
Sodium 2-acetamido-3-mercaptopropionate
Sodium, acetylcysteine
Solmucol
Temmler brand OF acetylcysteine
Teva brand OF acetylcysteine
Thiemann brand OF acetylcysteine
Trommsdorff brand OF acetylcysteine
UPSA brand OF acetylcysteine
Whitehall brand OF acetylcysteine
Zambon brand OF acetylcysteine
Zambon, nac
Zinc, acetylcysteine
Zyma brand OF acetylcysteine
|
|
19 |
|
Vorinostat |
Approved, Investigational |
Phase 1, Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
149647-78-9
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
m344
Merck brand of Vorinostat
Merck brand OF vorinostat
MK0683
MK-0683
MLS001065855
MolPort-003-850-293
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NCGC00168085-02
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
NHNPODA
N-Hydroxy-N'-phenyl octanediamide
|
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N'-hydroxy-N-phenyloctanediamide
N-hydroxy-N'-phenyloctanediamide
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
NSC701852
NSC-701852
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamate
suberoylanilide hydroxamic acid
Suberoylanilide hydroxamic acid
SW-064652
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat [USAN]
Vorinostat MSD
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
|
|
20 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
21 |
|
Busulfan |
Approved, Investigational |
Phase 2 |
|
55-98-1 |
2478 |
Synonyms:
1, {4-Bis[methanesulfonoxy]butane}
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonoxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
acid, tetramethylene ester
AI3-25012
AKOS003614975
alkylating agent: crosslinks guanine residues
Ambap55-98-1
AN 33501
B1022
B2635_FLUKA
B2635_SIGMA
Bisulfex
Bisulphex
BRN 1791786
BSPBio_001920
Busilvex
busulfan
Busulfan
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Busulfan (JP15/USP/INN)
Busulfan [INN:JAN]
Busulfan glaxosmithkline brand
Busulfan GlaxoSmithKline Brand
Busulfan orphan brand
Busulfan Orphan Brand
Busulfan wellcome
Busulfan Wellcome
Busulfan wellcome brand
Busulfan Wellcome Brand
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Busulphano
Busulphanum
butane-1,4-diyl dimethanesulfonate
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
Citosulfan
CPD000058613
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
Glaxo wellcome brand OF busulfan
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline brand OF busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
|
GT 2041
GT 41
HMS1920I07
HMS2091O09
HMS502K09
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
Leucosulfan
Leucosulphan
LS-1358
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MLS001076666
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myléran
MYLERAN (TN)
Myleran tablets
Myleran Tablets
Myleran, Busulfex, Busulfan
Mylerlan
n-Butane-1,3-di(methylsulfonate)
N-Butane-1,3-di(methylsulfonate)
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI60_041640
NCI-C01592
NCIMech_000192
NINDS_000847
NSC 750
NSC750
NSC-750
NSC-750sulphabutin
Orphan brand OF busulfan
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
Spectrum_000092
SPECTRUM1500152
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
ST50825921
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene {bis[methanesulfonate]}
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene Dimethane Sulfonate
Tetramethylenester kyseliny methansulfonove
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
Wellcome brand OF busulfan
Wellcome Brand of Busulfan
Wellcome, busulfan
Wellcome, Busulfan
WLN: WS1&O4OSW1
X 149
|
|
22 |
|
alemtuzumab |
Approved, Investigational |
Phase 2 |
|
216503-57-0 |
|
Synonyms:
|
23 |
|
Cysteine |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
52-90-4 |
5862 |
Synonyms:
(+)-2-Amino-3-mercaptopropionic acid
(2R)-2-Amino-3-mercaptopropanoate
(2R)-2-amino-3-mercaptopropanoic acid
(2R)-2-Amino-3-mercaptopropanoic acid
(2R)-2-Amino-3-sulfanylpropanoate
(2R)-2-amino-3-sulfanylpropanoic acid
(2R)-2-Amino-3-sulfanylpropanoic acid
(2R)-2-Amino-3-sulphanylpropanoate
(2R)-2-Amino-3-sulphanylpropanoic acid
(R)-(+)-Cysteine
(R)-2-Amino-3-mercaptopropanoate
(R)-2-Amino-3-mercapto-propanoate
(R)-2-Amino-3-mercaptopropanoic acid
(R)-2-Amino-3-mercapto-propanoic acid
(R)-Cysteine
2-Amino-3-mercaptopropanoate
2-Amino-3-mercaptopropanoic acid
2-Amino-3-mercaptopropionate
2-Amino-3-mercaptopropionic acid
3-Mercapto-L-alanine
Acetylcysteine
alpha-Amino-beta-thiolpropionic acid
beta-Mercaptoalanine
b-Mercaptoalanine
C
Carbocysteine
Cisteina
Cisteinum
|
Cys
Cystein
Cysteine
CYSTEINE
Cysteine hydrochloride
Cysteinum
e 920
e920
e-920
Ecolan
Free Cysteine
FREE cysteine
Half cystine
Half-cystine
L Cysteine
L-(+)-Cysteine
L-2-Amino-3-mercaptopropanoate
L-2-Amino-3-mercaptopropanoic acid
L-2-Amino-3-mercaptopropionate
L-2-Amino-3-mercaptopropionic acid
L-Cys
L-Cystein
L-cysteine
L-Zystein
Polycysteine
Thioserine
Zinc cysteinate
|
|
24 |
|
Glycine |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
56-40-6 |
750 |
Synonyms:
(1-13c)glycinato
(15N)Glycine
15527_RIEDEL
15527_SIAL
15743-44-9 (mono-potassium salt)
17829-66-2 (cobalt salt)
18875-39-3
2,2-dialkylglycines
2311-65-1
25718-94-9
29728-27-6 (monoammonium salt)
2-Aminoacetate
2-Aminoacetic acid
32817-15-5 (copper salt)
33226_RIEDEL
33226_SIAL
33242-26-1 (calcium salt)
35947-07-0 (calcium salt (2:1))
410225_SIAL
50046_FLUKA
50046_SIGMA
513-29-1 (sulfate (3:1))
52955-63-2
56-40-6
57678-19-0
6000-43-7 (hydrochloride)
6000-44-8 (mono-hydrochloride salt)
63183-41-5 (hydrochloride hydrogen carbonate)
71295-98-2 (phosphate (1:1))
7490-95-1 (hydrochloride (2:1)
7490-95-1 (hydrochloride (2:1))
7575-55-5
848646-45-7
87867-94-5
AB1002628
AB-131/40217813
AC1L19XW
AC1Q28JW
AC1Q53O0
Acid, aminoacetic
Acide aminoacetique
Acide aminoacetique [INN-French]
Acido aminoacetico
Acido aminoacetico [INN-Spanish]
Acidum aminoaceticum
Acidum aminoaceticum [INN-Latin]
Aciport
AI3-04085
AKOS000119626
Aminoacetate
Amino-acetate
aminoacetic acid
Aminoacetic acid
Amino-acetic acid
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER
Aminoazijnzuur
Aminoessigsaeure
Aminoessigsäure
Aminoethanoate
Aminoethanoic acid
Amitone
an alpha amino acid ester
AR-1A0345
AR-1A0532
B72BA06C-60E9-4A83-A24A-A2D7F465BB65
Biomol-NT_000195
bmse000089
BPBio1_001222
C00037
Calcium salt glycine
CCRIS 5915
CHEBI:15428
CHEBI:15705
CHEBI:16228
CHEMBL773
CID750
Cobalt salt glycine
Copper salt glycine
Corilin
CPD-8569
D00011
DB00145
EINECS 200-272-2
FEMA No. 3287
FT-0083159
G
G0099
G0317
G5417_SIGMA
G5523_SIGMA
|
G7126_SIGMA
G7403_SIGMA
G8790_SIGMA
G8898_SIGMA
Glicina
Glicina [INN-Spanish]
Glicoamin
gly
Gly
GLY (IUPAC abbrev)
Glycin
glycine
Glycine
Glycine (JP15/USP)
Glycine [INN]
GLYCINE 1.5% IN PLASTIC CONTAINER
Glycine carbonate (1:1), monosodium salt
Glycine carbonate (2:1), monolithium salt
Glycine carbonate (2:1), monopotassium salt
Glycine carbonate (2:1), monosodium salt
Glycine hydrochloride
Glycine hydrochloride (2:1)
Glycine iron sulphate (1:1)
Glycine phosphate
Glycine phosphate (1:1)
Glycine sulfate (3:1)
GLYCINE, ACS
Glycine, calcium salt
Glycine, calcium salt (2:1)
Glycine, cobalt salt
Glycine, copper salt
Glycine, homopolymer (VAN)
Glycine, labeled with carbon-14
Glycine, monoammonium salt
Glycine, monopotasssium salt
Glycine, monosodium salt
Glycine, non-medical
Glycine, sodium hydrogen carbonate
Glycine-UL-14C hydrochloride
Glycinum
Glycinum [INN-Latin]
Glycocoll
Glycolixir
Glycosthene
Glykokoll
Glyzin
Gyn-hydralin
H2N-CH2-COOH
Hampshire glycine
Hgly
H-Gly-OH
HSDB 495
Hydrochloride, glycine
InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5
KST-1A2919
KST-1A8102
L001246
L-alpha-amino acids
Leimzucker
L-Glycine
LS-218
MolPort-000-871-607
Monoammonium salt glycine
Monopotasssium salt glycine
Monosodium salt glycine
NCGC00024503-01
NCGC00024503-02
nchem.554-comp2
nchembio.121-comp9
nchembio.145-comp33
nchembio.198-comp12
NChemBio.2007.13-comp1
nchembio.265-comp9
nchembio.266-comp30
NSC 25936
NSC25936
P8791_SIGMA
Padil
Phosphate, glycine
polyglycine
Polyglycine II
S04-0135
Salt glycine, monoammonium
Salt glycine, monosodium
Sucre de gelatine
Tocris-0219
UNII-TE7660XO1C
W328707_ALDRICH
WLN: Z1VQ
|
|
25 |
|
Betadex |
Experimental |
Phase 1, Phase 2 |
|
7585-39-9 |
320761 |
Synonyms:
beta -Cycloamylose
beta -Cyclodextrin
beta Cyclodextrin, usan
beta -Cycloheptaamylose
beta-cyclodextrin
beta-Cyclodextrin
Betadex
Betadex, inn, usan
b-Schardinger dextran
Cyclodextrin B
|
Cyclo-epta-amylose
Cycloheptaamylose
Cyclo-hepta-amylose
Cycloheptaglucan
Cycloheptaglucosan
Cycloheptakis-(1->4)-(a-D-glucopyranose)
Cycloheptamaltose
Cycloheptapentylose
Cyclomaltoheptaose
e459
|
|
26 |
|
Protective Agents |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
Respiratory System Agents |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
Antioxidants |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
N-monoacetylcystine |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
Expectorants |
|
Phase 1, Phase 2 |
|
|
|
31 |
|
Antidotes |
|
Phase 1, Phase 2 |
|
|
|
32 |
|
Histone Deacetylase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
33 |
|
Bilirubin |
|
Phase 1, Phase 2 |
|
635-65-4 |
5280352 |
Synonyms:
(4Z,15Z)-Bilirubin ixa
(Z,Z)-Bilirubin ixa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionic acid
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoic acid
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoate
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
|
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
8,12-Bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbiladiene-ac-1,19(21H,24H)-dione
Bilirubin IX alpha
Bilirubin ixalpha
Bilirubin IX-alpha
Bilirubin(Z,Z)
Bilirubin-ixalpha
Cholerythrin
Hematoidin
|
|
34 |
|
Liver Extracts |
|
Phase 1, Phase 2 |
|
|
|
35 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
36 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
37 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
38 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
39 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
40 |
|
Leucine |
Investigational, Nutraceutical |
Phase 2 |
|
61-90-5 |
6106 |
Synonyms:
(2S)-2-Amino-4-methylpentanoate
(2S)-2-Amino-4-methylpentanoic acid
(2S)-a-2-Amino-4-methylvalerate
(2S)-a-2-Amino-4-methylvaleric acid
(2S)-a-Leucine
(2S)-alpha-2-Amino-4-methylvalerate
(2S)-alpha-2-Amino-4-methylvaleric acid
(2S)-alpha-Leucine
(2S)-Α-2-amino-4-methylvalerate
(2S)-Α-2-amino-4-methylvaleric acid
(2S)-Α-leucine
(S)-(+)-Leucine
(S)-2-Amino-4-methylpentanoate
(S)-2-Amino-4-methylpentanoic acid
(S)-2-Amino-4-methylvalerate
(S)-2-Amino-4-methylvaleric acid
(S)-Leucine
2-Amino-4-methylvalerate
|
2-Amino-4-methylvaleric acid
4-Methyl-L-norvaline
L
L-(+)-Leucine
L-a-Aminoisocaproate
L-a-Aminoisocaproic acid
L-alpha-Aminoisocaproate
L-alpha-Aminoisocaproic acid
Leu
Leucine
LEUCINE
Leucine, L isomer
Leucine, L-isomer
L-Isomer leucine
L-Leucin
L-Leucine
L-Leuzin
|
|
41 |
|
Lithium carbonate |
Approved |
Early Phase 1 |
|
554-13-2 |
|
Synonyms:
Carbonic acid, dilithium salt
Dilithium carbonate
Lithii carbonas
|
Lithium carbonate
Lithonate
|
|
42 |
|
Antidepressive Agents |
|
Early Phase 1 |
|
|
|
43 |
|
Psychotropic Drugs |
|
Early Phase 1 |
|
|
|
44 |
|
Complement System Proteins |
|
|
|
|
|
Interventional clinical trials:
(show all 44)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects |
Recruiting |
NCT03910621 |
Phase 4 |
Miglustat |
2 |
Application of Miglustat in Patients With Niemann-Pick Type C |
Completed |
NCT01760564 |
Phase 3 |
Miglustat |
3 |
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation |
Completed |
NCT00176904 |
Phase 2, Phase 3 |
Busulfan, Cyclophosphamide, Antithymocyte Globulin |
4 |
A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency |
Active, not recruiting |
NCT02004691 |
Phase 2, Phase 3 |
placebo (saline);GZ402665 |
5 |
A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease |
Active, not recruiting |
NCT02534844 |
Phase 2, Phase 3 |
VTS-270 |
6 |
Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C |
Active, not recruiting |
NCT02612129 |
Phase 2, Phase 3 |
arimoclomol;Placebo |
7 |
A Phase 2b/3 Open-label Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 Disease Previously Treated Under Protocol VTS301 |
Active, not recruiting |
NCT03879655 |
Phase 2, Phase 3 |
VTS-270 |
8 |
Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC) |
Active, not recruiting |
NCT03643562 |
Phase 3 |
Adrabetadex |
9 |
A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Aged <18 Years With Acid Sphingomyelinase Deficiency |
Completed |
NCT02292654 |
Phase 1, Phase 2 |
Olipudase alfa |
10 |
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine |
Completed |
NCT00975689 |
Phase 1, Phase 2 |
N-Acetyl Cysteine |
11 |
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 |
Completed |
NCT02124083 |
Phase 1, Phase 2 |
Vorinostat |
12 |
Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor |
Completed |
NCT00730314 |
Phase 1, Phase 2 |
|
13 |
A Phase II Randomized Controlled Study of Miglustat in Adult and Juvenile Patients With Niemann-Pick Type C Disease |
Completed |
NCT00517153 |
Phase 2 |
miglustat |
14 |
Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1 |
Recruiting |
NCT03887533 |
Phase 1, Phase 2 |
VTS-270 |
15 |
A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency |
Active, not recruiting |
NCT02004704 |
Phase 2 |
GZ402665 |
16 |
Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C |
Active, not recruiting |
NCT03471143 |
Phase 1, Phase 2 |
2-Hydroxypropyl-Beta-Cyclodextrin |
17 |
A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C NPC-1 and the Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes |
Active, not recruiting |
NCT02912793 |
Phase 1, Phase 2 |
Hydroxypropyl-beta-cyclodextrin |
18 |
Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study. |
Active, not recruiting |
NCT03759639 |
Phase 2 |
IB1001 |
19 |
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders |
Active, not recruiting |
NCT01372228 |
Phase 1, Phase 2 |
|
20 |
Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation |
Terminated |
NCT00668564 |
Phase 2 |
Cyclophosphamide;Campath-1H;Busulfan |
21 |
An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease |
Withdrawn |
NCT03687476 |
Phase 2 |
VTS-270 |
22 |
A Phase I/II Randomized, Controlled Study of OGT 918 in Adult and Juvenile Patients With Niemann Pick C Disease |
Completed |
NCT00316498 |
Phase 1 |
OGT918 |
23 |
A Phase I Study to Evaluate the Single and Multiple-dose Pharmacokinetics of Intravenous Trappsol Cyclo (HP-Beta-CD) in Patients With Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing Upon Biomarkers of NPC Disease |
Completed |
NCT02939547 |
Phase 1 |
Hydroxypropyl-beta-cyclodextrin |
24 |
Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease |
Completed |
NCT01747135 |
Phase 1 |
VTS-270 |
25 |
An Open-label, Multicenter, Ascending Dose Study of the Tolerability and Safety of Recombinant Human Acid Sphingomyelinase (rhASM) in Patients With Acid Sphingomyelinase Deficiency (ASMD) |
Completed |
NCT01722526 |
Phase 1 |
Recombinant human acid sphingomyelinase |
26 |
Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells |
Recruiting |
NCT02254863 |
Phase 1 |
|
27 |
An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol® Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C (NPC-1) |
Active, not recruiting |
NCT03893071 |
Phase 1 |
Hydroxypropyl-β-cyclodextrin |
28 |
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders |
Active, not recruiting |
NCT01586455 |
Phase 1 |
Human Placental Derived Stem Cell |
29 |
A Phase I, Single-Center, Single Dose, Dose Escalation Study of Recombinant Human Acid Sphingomyelinase (rhASM) in Adults With Acid Sphingomyelinase Deficiency (ASMD) |
Terminated |
NCT00410566 |
Phase 1 |
rhASM;rhASM;rhASM;rhASM;rhASM |
30 |
Investigating Lysosomal Storage Diseases in Minority Groups |
Unknown status |
NCT02120235 |
|
|
31 |
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation |
Unknown status |
NCT00005900 |
|
|
32 |
Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Hepatic and Neurological Niemann Pick Disease |
Completed |
NCT03883750 |
|
|
33 |
Understanding Health Insurance Literacy and Challenges in Accessing Health Services in Niemann-Pick Disease Through the Eyes of Patients and Families |
Completed |
NCT04469894 |
|
|
34 |
Longitudinal Study of Cognition With Niemann-Pick Disease, Type C |
Completed |
NCT01899950 |
|
|
35 |
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern |
Completed |
NCT02435030 |
|
|
36 |
Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and Disease |
Completed |
NCT00001972 |
|
15 O Water |
37 |
A Prospective and Retrospective Cohort Study to Refine and Expand the Knowledge on Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD) |
Recruiting |
NCT04106544 |
|
|
38 |
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C |
Recruiting |
NCT00344331 |
|
|
39 |
Longitudinal Study of Neurodegenerative Disorders |
Recruiting |
NCT03333200 |
|
|
40 |
a Single-center, Prospective, Open, and Non-randomized Case-control Study of Lithium Carbonate Effect on Niemann Disease C1 Type |
Active, not recruiting |
NCT03201627 |
Early Phase 1 |
Lithium Carbonate |
41 |
Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study |
Active, not recruiting |
NCT01306604 |
|
|
42 |
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US |
Available |
NCT04316637 |
|
Arimoclomol |
43 |
Complement Activation in the Lysosomal Storage Disorders |
Not yet recruiting |
NCT04189601 |
|
|
44 |
Study Qbout the Screening of Niemann-Pick Disease, Type C in a Psychiatric Population |
Terminated |
NCT02841358 |
|
|
|